Helen V Alderson1, James P Ritchie2, Sabrina Pagano3, Rachel J Middleton2, Menno Pruijm4, Nicolas Vuilleumier3, Philip A Kalra2. 1. Vascular Research Group, Manchester Academic Health Sciences Centre, University of Manchester, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom; Helen.alderson@manchester.ac.uk. 2. Vascular Research Group, Manchester Academic Health Sciences Centre, University of Manchester, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom. 3. Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland; and. 4. Division of Nephrology and Hypertension, Department of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Abstract
BACKGROUND AND OBJECTIVES: Elevated levels of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin are associated with negative outcomes in CKD. Our study aimed to explore the prognostic accuracy of blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for progression to ESRD, major adverse cardiovascular events, and death in a large cohort of adult patients with all-cause nondialysis-dependent CKD stages 3-5. We considered whether these factors improve prediction in relation to traditional biomarkers and clinical parameters. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were measured on baseline plasma samples from 1982 patients who were recruited to the Chronic Renal Insufficiency Standards Implementation Study between the start of June of 2002 and the start of June of 2013. Associations with study end points were assessed using Cox regression models, receiver operator characteristic curve analyses, and reclassification statistics. RESULTS: Over a median follow-up of 29.5 months (interquartile range, 14.9-53.5), 21.6% of patients progressed to ESRD, 27% died, and 6.6% suffered a major adverse cardiovascular event. Higher blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were independently associated with a greater risk for ESRD (hazard ratio, 1.25; 95% confidence interval, 1.10 to 1.43; P<0.001 and hazard ratio, 1.35; 95% confidence interval, 1.14 to 1.59; P≤0.001, respectively, per 1 SD higher biomarker concentration). There was no association with risk for cardiovascular events or death. The addition of biomarkers to our baseline risk model of traditional clinical characteristics and laboratory parameters did not significantly improve model discrimination or risk reclassification. CONCLUSIONS: In patients with moderate to severe CKD, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin blood levels are independent risk factors for progression to ESRD. Additional studies are needed to establish the utility and cost-effectiveness of these novel biomarkers in the clinical setting.
BACKGROUND AND OBJECTIVES: Elevated levels of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin are associated with negative outcomes in CKD. Our study aimed to explore the prognostic accuracy of blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for progression to ESRD, major adverse cardiovascular events, and death in a large cohort of adult patients with all-cause nondialysis-dependent CKD stages 3-5. We considered whether these factors improve prediction in relation to traditional biomarkers and clinical parameters. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were measured on baseline plasma samples from 1982 patients who were recruited to the Chronic Renal Insufficiency Standards Implementation Study between the start of June of 2002 and the start of June of 2013. Associations with study end points were assessed using Cox regression models, receiver operator characteristic curve analyses, and reclassification statistics. RESULTS: Over a median follow-up of 29.5 months (interquartile range, 14.9-53.5), 21.6% of patients progressed to ESRD, 27% died, and 6.6% suffered a major adverse cardiovascular event. Higher blood levels of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin were independently associated with a greater risk for ESRD (hazard ratio, 1.25; 95% confidence interval, 1.10 to 1.43; P<0.001 and hazard ratio, 1.35; 95% confidence interval, 1.14 to 1.59; P≤0.001, respectively, per 1 SD higher biomarker concentration). There was no association with risk for cardiovascular events or death. The addition of biomarkers to our baseline risk model of traditional clinical characteristics and laboratory parameters did not significantly improve model discrimination or risk reclassification. CONCLUSIONS: In patients with moderate to severe CKD, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin blood levels are independent risk factors for progression to ESRD. Additional studies are needed to establish the utility and cost-effectiveness of these novel biomarkers in the clinical setting.
Authors: Helen Eddington; Richard Hoefield; Smeeta Sinha; Constantina Chrysochou; Beverley Lane; Robert N Foley; Janet Hegarty; John New; Donal J O'Donoghue; Rachel J Middleton; Philip A Kalra Journal: Clin J Am Soc Nephrol Date: 2010-08-05 Impact factor: 8.237
Authors: Richard A Hoefield; Philip A Kalra; Patricia Baker; Beverley Lane; John P New; Donal J O'Donoghue; Robert N Foley; Rachel J Middleton Journal: Am J Kidney Dis Date: 2010-08-08 Impact factor: 8.860
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Venkata S Sabbisetti; Sushrut S Waikar; Daniel J Antoine; Adam Smiles; Chang Wang; Abinaya Ravisankar; Kazumi Ito; Sahil Sharma; Swetha Ramadesikan; Michelle Lee; Rebeccah Briskin; Philip L De Jager; Thanh Thu Ngo; Mark Radlinski; James W Dear; Kevin B Park; Rebecca Betensky; Andrzej S Krolewski; Joseph V Bonventre Journal: J Am Soc Nephrol Date: 2014-06-05 Impact factor: 10.121
Authors: Kathleen D Liu; Wei Yang; Amanda H Anderson; Harold I Feldman; Sevag Demirjian; Takayuki Hamano; Jiang He; James Lash; Eva Lustigova; Sylvia E Rosas; Michael S Simonson; Kaixiang Tao; Chi-yuan Hsu Journal: Kidney Int Date: 2013-01-23 Impact factor: 10.612
Authors: Isha S Dhande; Stacy M Cranford; Yaming Zhu; Sterling C Kneedler; M John Hicks; Scott E Wenderfer; Michael C Braun; Peter A Doris Journal: Hypertension Date: 2018-02-05 Impact factor: 10.190
Authors: Franz Schaefer; Howard Trachtman; Elke Wühl; Marietta Kirchner; Salim S Hayek; Ali Anarat; Ali Duzova; Sevgi Mir; Dusan Paripovic; Alev Yilmaz; Francesca Lugani; Klaus Arbeiter; Mieczyslaw Litwin; Jun Oh; Maria Chiara Matteucci; Jutta Gellermann; Simone Wygoda; Augustina Jankauskiene; Günter Klaus; Jiri Dusek; Sara Testa; Aleksandra Zurowska; Alberto Caldas Afonso; Melissa Tracy; Changli Wei; Sanja Sever; William Smoyer; Jochen Reiser Journal: JAMA Pediatr Date: 2017-11-06 Impact factor: 16.193
Authors: Federica Piani; Isabella Melena; Cameron Severn; Linh T Chung; Carissa Vinovskis; David Cherney; Laura Pyle; Carlos A Roncal-Jimenez; Miguel A Lanaspa; Arleta Rewers; Daniël H van Raalte; Wassim Obeid; Chirag Parikh; Robert G Nelson; Meda E Pavkov; Kristen J Nadeau; Richard J Johnson; Petter Bjornstad Journal: Pediatr Diabetes Date: 2021-09-06 Impact factor: 4.866
Authors: Melanie H Jacobson; Yinxiang Wu; Mengling Liu; Kurunthachalam Kannan; Adela Jing Li; Morgan Robinson; Bradley A Warady; Susan Furth; Howard Trachtman; Leonardo Trasande Journal: Environ Int Date: 2021-05-02 Impact factor: 13.352
Authors: Il Young Kim; June Hyun Kim; Min Jeong Kim; Dong Won Lee; Cheol Gu Hwang; Miyeun Han; Harin Rhee; Sang Heon Song; Eun Young Seong; Soo Bong Lee Journal: PLoS One Date: 2018-10-16 Impact factor: 3.240
Authors: Jason H Greenberg; Alison G Abraham; Yunwen Xu; Jeffrey R Schelling; Harold I Feldman; Venkata S Sabbisetti; Mariana Cardenas Gonzalez; Steven Coca; Sarah J Schrauben; Sushrut S Waikar; Vasan S Ramachandran; Michael G Shlipak; Bradley Warady; Paul L Kimmel; Joseph V Bonventre; Michelle Denburg; Chirag R Parikh; Susan Furth Journal: J Am Soc Nephrol Date: 2020-03-31 Impact factor: 14.978